De Francesco Ticiana

Armstrong James J, De Francesco Ticiana, Beckers Henny J, Stalmans Ingeborg, Fea Antonio M, Sng Chelvin C A et al.

This study compared three primary glaucoma surgeries, finding SIBS microshunt achieved higher success and fewer complications than gelatin microstent or trabeculectomy, suggesting it's a superior option.

Calvo Ernesto, De Francesco Ticiana, Vera Lautaro, Tyson Farrell, Weinreb Robert N

This study found cyclodialysis with scleral allograft reinforcement during cataract surgery effectively lowered IOP by 34% in POAG patients, offering a safe, combined surgical option.

Chee Soon-Phaik, Weikert Mitchell P, Wallace Ryan, De Francesco Ticiana, Ahmed Ike, Fram Nicole et al.

This case describes a traumatic cataract with extensive zonular damage and iridodialysis, highlighting the complex surgical challenges and financial constraints in managing such post-trauma complications.

Muayad Jawad, Loya Asad, Hussain Zain S, Chauhan Muhammad Z, Alsoudi Amer F, De Francesco Ticiana et al.

GLP-1 agonists significantly lowered glaucoma risk (POAG, ocular hypertension, treatment need) compared to metformin in type 2 diabetics, suggesting potential ocular benefits beyond diabetes management.

De Francesco Ticiana, Mikula Eric, Lummis Wes, Sangalang Nathan, Ahmed Iqbal Ike K

This ex vivo study found standard gonioscopy, SLT, and laser iridotomy lenses significantly elevate IOP (around 20 mmHg), highlighting potential pressure spikes during these common procedures.

Ahmed Iqbal Ike K, Sheybani Arsham, De Francesco Ticiana, Samuelson Thomas W

This 5-year study found iStent inject comparable to phacoemulsification alone regarding corneal endothelial cell loss, whereas Hydrus and CyPass showed significantly greater loss, impacting long-term corneal health.

Samuelson Thomas W, De Francesco Ticiana, Ahmed Iqbal Ike K, Gedde Steven J, Paranjpe Vikram R, Singh Kuldev et al.

This case highlights managing severe progressive glaucoma after failed MIGS and medical therapy, where trabeculectomy achieved stability in one eye, emphasizing its role for advanced disease.

Huang Marshall J, Samuelson Thomas W, De Francesco Ticiana, Levin Ariana, Sieck Erin, Gazzard Gus et al.

This case highlights managing severe glaucoma in a second eye after complex, suboptimal surgical outcomes in the first eye, emphasizing individualized treatment and considering novel devices for challenging cases.

Schlenker Matthew B, Armstrong James J, De Francesco Ticiana, Ahmed Iqbal Ike K

This study found SIBS microshunt with MMC provides good 1-year glaucoma control and medication reduction, but success rates are lower in refractory eyes, combined procedures, and with insufficient MMC.

Nagy Zoltan Z, Kranitz Kinga, Ahmed Iqbal Ike K, De Francesco Ticiana, Mikula Eric, Juhasz Tibor

A pilot study of FLIGHT femtosecond laser trabeculotomy for glaucoma showed excellent safety and sustained IOP reduction (34.6% at 24 months) with patent channels, indicating a promising new treatment option.

Ahmed Iqbal Ike K, Sheybani Arsham, De Francesco Ticiana, Lass Jonathan H, Benetz Beth Ann, Samuelson Thomas W et al.

This 5-year study found iStent inject with phacoemulsification for glaucoma had no device-related complications or worse endothelial cell loss than phacoemulsification alone, demonstrating long-term corneal safety.

Ten Hulzen Richard D, Wagner Isabella V, Aref Ahmad A, Provencher Lorraine M, Razeghinejad Reza, Danesh-Meyer Helen V et al.

A misplanted glaucoma minishunt was found piercing the iris and capsular bag, embedding in the cataract. This "deadbolt" effect complicates cataract surgery and highlights the importance of precise shunt placement.

Ahmed Iqbal Ike K, De Francesco Ticiana, Rhee Douglas, McCabe Cathleen, Flowers Brian, Gazzard Gus et al.

The HORIZON trial found that adding a Schlemm's canal microstent to cataract surgery significantly improved long-term IOP control, reduced medication use, and lowered the need for further glaucoma surgery compared to cataract surgery alone.